HepaStem
BiologicalHepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
NCT Number: NCT02489292
The aim of the study is to assess the efficacy of HepaStem treatment in paediatric patients suffering from urea cycle disorders.
Looking for future studies?
Notify MeUp to 12 year
All sexes
Interventional
Phase 2
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
Main Exclusion Criteria:
HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
Time frame: at 6m post-first infusion day
Time frame: at 3, 9 and 12 months post-first infusion day
Time frame: up to 12 months post-first infusion day
Time frame: up to 12 months post-first infusion day
Time frame: up to 12 months post-first infusion day
Time frame: up to 12 months post-first infusion day
Time frame: up to 12 months post-first infusion day
Time frame: up to 12 months post-first infusion day
Safety evaluation in terms of (1) clinical status, (2) portal vein hemodynamics, (3) morphology of the liver, bile ducts and portal system, (4) laboratory tests, (5) De novo detection of donor-specific circulating anti-human leukocyte antigen (HLA) antibodies, and/or other immune-related markers, (6) serious adverse events and clinically significant adverse events related to HepaStem, technical intervention, and concomitant treatments.
Cellaion SA
Industry
Prospective, Open Label, Multicenter, Efficacy and Safety Study of Several Infusions of HepaStem in Urea Cycle Disorders Paediatric Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01257737
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT00947544
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT01347073
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Los Angeles, California, United States
View Trial DetailsNCT00947297
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Long Beach, California, United States
View Trial Details